Vertex Pharmaceuticals (MA) (VRTX) Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer
9/4/2012 10:13:02 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Stuart A. Arbuckle as Executive Vice President and Chief Commercial Officer. Mr. Arbuckle has more than 25 years of experience in leading global sales and marketing efforts at biopharmaceutical companies. He will oversee Vertex’s commercial team, which is responsible for the company’s sales, marketing, patient support, market research and other activities that support the approved use of INCIVEK® (telaprevir) in the U.S. and the ongoing global launch of KALYDECOTM (ivacaftor). Mr. Arbuckle will begin his employment with Vertex effective today and will serve as a member of Vertex’s executive team, reporting directly to the company’s Chairman, President and Chief Executive Officer, Jeffrey Leiden, M.D., Ph.D.